IL180786A - A gene expression modulation method by modifying cpg content - Google Patents

A gene expression modulation method by modifying cpg content

Info

Publication number
IL180786A
IL180786A IL180786A IL18078607A IL180786A IL 180786 A IL180786 A IL 180786A IL 180786 A IL180786 A IL 180786A IL 18078607 A IL18078607 A IL 18078607A IL 180786 A IL180786 A IL 180786A
Authority
IL
Israel
Prior art keywords
leu
thr
nucleic acid
ser
expression
Prior art date
Application number
IL180786A
Other languages
English (en)
Hebrew (he)
Other versions
IL180786A0 (en
Original Assignee
Geneart Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35839637&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL180786(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE102004037611A external-priority patent/DE102004037611B4/de
Priority claimed from DE200410037652 external-priority patent/DE102004037652B4/de
Application filed by Geneart Ag filed Critical Geneart Ag
Publication of IL180786A0 publication Critical patent/IL180786A0/en
Publication of IL180786A publication Critical patent/IL180786A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43595Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from coelenteratae, e.g. medusae
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/46Vector systems having a special element relevant for transcription elements influencing chromatin structure, e.g. scaffold/matrix attachment region, methylation free island
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Electrotherapy Devices (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
  • Control Of Electric Motors In General (AREA)
IL180786A 2004-08-03 2007-01-18 A gene expression modulation method by modifying cpg content IL180786A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102004037611A DE102004037611B4 (de) 2004-08-03 2004-08-03 Induzierbare Genexpression
DE200410037652 DE102004037652B4 (de) 2004-08-03 2004-08-03 Verfahren zur Modulation der Genexpression durch Änderung des CpG Gehalts
PCT/EP2005/008423 WO2006015789A2 (fr) 2004-08-03 2005-08-03 Procede pour moduler l'expression genique par modification de la teneur en cpg

Publications (2)

Publication Number Publication Date
IL180786A0 IL180786A0 (en) 2007-06-03
IL180786A true IL180786A (en) 2013-08-29

Family

ID=35839637

Family Applications (1)

Application Number Title Priority Date Filing Date
IL180786A IL180786A (en) 2004-08-03 2007-01-18 A gene expression modulation method by modifying cpg content

Country Status (14)

Country Link
US (4) US8859275B2 (fr)
EP (1) EP1776460B8 (fr)
JP (1) JP4550115B2 (fr)
KR (1) KR101222628B1 (fr)
AT (1) ATE453716T1 (fr)
AU (1) AU2005270430B2 (fr)
BR (1) BRPI0513081A (fr)
CA (1) CA2575490A1 (fr)
DE (1) DE502005008794D1 (fr)
DK (1) DK1776460T3 (fr)
HK (1) HK1100089A1 (fr)
IL (1) IL180786A (fr)
MX (1) MX2007001292A (fr)
WO (1) WO2006015789A2 (fr)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0513081A (pt) * 2004-08-03 2008-04-22 Geneart Ag método para modular a expressão gênica pela alteração do conteúdo de cpg, sistema de expressão, medicamento que o compreende e respectivos usos
CA2636111C (fr) 2006-01-13 2018-04-03 The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health Genes il-15 et il-15r-alpha a codon optimise destines a l'expression dans les cellules mammaliennes
GB0606190D0 (en) 2006-03-28 2006-05-10 Isis Innovation Construct
EP2089513A1 (fr) 2006-12-07 2009-08-19 Publiekrechtelijke rechtspersoon Academisch Ziekenhuis Leiden h.o.d.n. Leids Universitair Medisch Centrum Utilisation d'un inhibiteur de tap d'un varicellovirus pour l'induction d'une immunité spécifique d'une tumeur ou d'un virus contre les teipp
BRPI0811466A2 (pt) 2007-05-07 2014-10-14 Medimmune Llc Anticorpo anti-icos isolado, ácido nucleico, vetor, célula isolada, métodos para produzir um anticorpo, para tratar uma doença ou distúrbio, para tratar ou prevenir a rejeição em um paciente de transplante humano, para tratar uma malignidade de célula t em um ser humano, para esgotar células t que expressam icos em um paciente humano, para romper a arquitetura do centro germinal em um órgão linfóide secundário de um primata, para esgotar células b centrais germinais de órgão linfóide secundário de um primata, e para esgotar células b comutadas em classes circulantes em um primata, e, composição farmacêutica.
EP2019134A1 (fr) * 2007-07-26 2009-01-28 Vision 7 GmbH Thérapie génique pour traiter la granulomatose septique chronique
US8697417B2 (en) 2007-07-26 2014-04-15 Uniqure Ip B.V. Baculoviral vectors comprising repeated coding sequences with differential codon biases
CA2750811C (fr) 2009-01-30 2017-08-29 Amsterdam Molecular Therapeutics (Amt) Ip B.V. Produits therapeutiques a base d'alanine-glyoxylate aminotransferase
EP2534264A4 (fr) * 2010-02-09 2014-02-26 Univ Columbia Procédés de modification d'expression et de solubilité de polypeptides
AU2011336707A1 (en) 2010-11-29 2013-07-04 Dako Denmark A/S Methods and systems for analyzing images of specimens processed by a programmable quantitative assay
DE102010056289A1 (de) 2010-12-24 2012-06-28 Geneart Ag Verfahren zur Herstellung von Leseraster-korrekten Fragment-Bibliotheken
WO2013030827A1 (fr) 2011-09-01 2013-03-07 Genome Compiler Corporation Système de conception, de visualisation et de transaction de constructions polynucléotidiques en vue de leur production
US20130109596A1 (en) 2011-09-26 2013-05-02 Life Technologies Corporation High efficiency, small volume nucleic acid synthesis
US20130274129A1 (en) 2012-04-04 2013-10-17 Geneart Ag Tal-effector assembly platform, customized services, kits and assays
US10563240B2 (en) 2013-03-14 2020-02-18 Life Technologies Corporation High efficiency, small volume nucleic acid synthesis
PL3030682T3 (pl) 2013-08-05 2020-11-16 Twist Bioscience Corporation Biblioteki genowe syntezowane de novo
EP3035961A1 (fr) * 2013-08-21 2016-06-29 CureVac AG Vaccin antirabique
SG10201801431TA (en) 2013-08-21 2018-04-27 Curevac Ag Respiratory syncytial virus (rsv) vaccine
BR112016000889A2 (pt) * 2013-08-21 2017-12-12 Curevac Ag composição e vacina para tratamento de câncer de próstata
CN110195072A (zh) 2013-08-21 2019-09-03 库瑞瓦格股份公司 狂犬病疫苗
EP3586871A3 (fr) * 2013-08-21 2020-03-11 CureVac AG Vaccin contre le virus respiratoire syncytial (rsv)
HUE046469T2 (hu) * 2013-08-21 2020-03-30 Curevac Ag Készítmény és vakcina tüdõrák kezelésére
EP3574916A1 (fr) * 2013-08-21 2019-12-04 CureVac AG Composition et vaccin pour le traitement du cancer du poumon
EP3218508A4 (fr) * 2014-11-10 2018-04-18 Modernatx, Inc. Optimisation d'acides nucléiques à plusieurs paramètres
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
CN107532129B (zh) 2014-12-09 2022-09-13 生命技术公司 高效小体积核酸合成
WO2016126882A1 (fr) 2015-02-04 2016-08-11 Twist Bioscience Corporation Procédés et dispositifs pour assemblage de novo d'acide oligonucléique
WO2016172377A1 (fr) 2015-04-21 2016-10-27 Twist Bioscience Corporation Dispositifs et procédés pour la synthèse de banques d'acides oligonucléiques
EP3294885B1 (fr) 2015-05-08 2020-07-01 CureVac Real Estate GmbH Procédé de production d'arn
PT3303583T (pt) 2015-05-29 2020-07-07 Curevac Ag Um método para produção e purificação de rna, compreendendendo pelo menos um passo de filtração por fluxo tangencial
KR20180050411A (ko) 2015-09-18 2018-05-14 트위스트 바이오사이언스 코포레이션 올리고핵산 변이체 라이브러리 및 그의 합성
US11512347B2 (en) 2015-09-22 2022-11-29 Twist Bioscience Corporation Flexible substrates for nucleic acid synthesis
CN115920796A (zh) 2015-12-01 2023-04-07 特韦斯特生物科学公司 功能化表面及其制备
AU2017315294B2 (en) 2016-08-22 2023-12-21 Twist Bioscience Corporation De novo synthesized nucleic acid libraries
JP6871364B2 (ja) 2016-09-21 2021-05-12 ツイスト バイオサイエンス コーポレーション 核酸に基づくデータ保存
EP3538549A1 (fr) 2016-11-10 2019-09-18 iOmx Therapeutics AG Protéines de liaison à l'antigène or10h1 et leurs utilisations
US10907274B2 (en) 2016-12-16 2021-02-02 Twist Bioscience Corporation Variant libraries of the immunological synapse and synthesis thereof
JP2020508661A (ja) 2017-02-22 2020-03-26 ツイスト バイオサイエンス コーポレーション 核酸ベースのデータ保存
WO2018170169A1 (fr) 2017-03-15 2018-09-20 Twist Bioscience Corporation Banques de variants de la synapse immunologique et leur synthèse
JP2020517259A (ja) 2017-04-19 2020-06-18 ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム 操作された抗原受容体を発現する免疫細胞
KR102628876B1 (ko) 2017-06-12 2024-01-23 트위스트 바이오사이언스 코포레이션 심리스 핵산 어셈블리를 위한 방법
WO2018231864A1 (fr) 2017-06-12 2018-12-20 Twist Bioscience Corporation Méthodes d'assemblage d'acides nucléiques continus
KR20200047706A (ko) 2017-09-11 2020-05-07 트위스트 바이오사이언스 코포레이션 Gpcr 결합 단백질 및 이의 합성 방법
CN111565834B (zh) 2017-10-20 2022-08-26 特韦斯特生物科学公司 用于多核苷酸合成的加热的纳米孔
CA3088911A1 (fr) 2018-01-04 2019-07-11 Twist Bioscience Corporation Dispositif de stockage a base d'adn et methode de synthese de polynucleotides utilisant le dispositif
EP3508499A1 (fr) 2018-01-08 2019-07-10 iOmx Therapeutics AG Anticorps ciblant et d'autres modulateurs d'un gène d'immunoglobuline associé à une résistance contre des réponses immunitaires antitumorales et leurs utilisations
US20210163922A1 (en) 2018-03-19 2021-06-03 Modernatx, Inc. Assembly and error reduction of synthetic genes from oligonucleotides
AU2019270243A1 (en) 2018-05-18 2021-01-07 Twist Bioscience Corporation Polynucleotides, reagents, and methods for nucleic acid hybridization
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
CA3131691A1 (fr) 2019-02-26 2020-09-03 Twist Bioscience Corporation Banques d'acides nucleiques variants pour l'optimisation d'anticorps
AU2020229349A1 (en) 2019-02-26 2021-10-14 Twist Bioscience Corporation Variant nucleic acid libraries for GLP1 receptor
AU2020298294A1 (en) 2019-06-21 2022-02-17 Twist Bioscience Corporation Barcode-based nucleic acid sequence assembly
US20230144548A1 (en) * 2019-06-30 2023-05-11 John Fraser Wright Recombinant aav vectors with altered immunogencity and methods of making the same
CN114401992A (zh) 2019-07-05 2022-04-26 艾欧麦克斯治疗股份公司 结合igsf11(vsig3)的igc2的抗体及其用途
WO2021061829A1 (fr) 2019-09-23 2021-04-01 Twist Bioscience Corporation Banques d'acides nucléiques variants pour crth2
EP3822288A1 (fr) 2019-11-18 2021-05-19 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Anticorps ciblant et autres modulateurs de l'antigène cd276 et leurs utilisations
US20240010720A1 (en) 2020-07-06 2024-01-11 Iomx Therapeutics Ag Antibodies binding igv of igsf11 (vsig3) and uses thereof
WO2022018516A1 (fr) * 2020-07-21 2022-01-27 Inspirar Limited Composition et méthode pour traiter des maladies oculaires
EP3992205A1 (fr) 2020-11-03 2022-05-04 Rheinische Friedrich-Wilhelms-Universität Bonn Composés de liaison de protéine de spicule du sars coronavirus-2
CA3173151A1 (fr) 2020-11-03 2022-05-12 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts Anticorps anti-cd28 bispecifiques et bivalents, co-stimulants, restreints a une cellule cible
WO2022106205A1 (fr) 2020-11-18 2022-05-27 Rheinische Friedrich-Wilhelms-Universität Bonn Composés de liaison à la protéine de spicule du coronavirus
WO2022184845A1 (fr) 2021-03-03 2022-09-09 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Anticorps bispécifiques améliorant les réponses immunitaires à médiation cellulaire
US20240350674A1 (en) * 2021-08-11 2024-10-24 Solid Biosciences Inc. Treatment of muscular dystrophy
CN118077011A (zh) * 2022-09-30 2024-05-24 南京金斯瑞生物科技有限公司 一种降低外源核酸免疫原性的密码子优化
WO2024133940A2 (fr) 2022-12-23 2024-06-27 Iomx Therapeutics Ag Protéines de liaison à un antigène (abp) inter-spécifiques ciblant une sous-famille b1 de récepteur de type immunoglobuline leucocytaire (lilrb1) et lilrb2, combinaisons et utilisations associées

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050131267A1 (en) * 1995-06-07 2005-06-16 Talmadge Karen D. System and method for delivering a therapeutic agent for bone disease
WO1998052581A1 (fr) * 1997-05-20 1998-11-26 Ottawa Civic Hospital Loeb Research Institute Vecteurs et procedes destines a l'immunisation et a des protocoles therapeutiques
UA77152C2 (en) * 1999-09-25 2006-11-15 Method for stimulation of immune response using nucleic acid-containing immunostimulating compositions, method for treatment of cancer and method for treatment or prophylaxis of allergy or asthma
ATE319814T1 (de) 2000-03-15 2006-03-15 Prolume Ltd Luciferase, fluoreszenzproteine, für luciferase und fluoreszenzproteine kodierend nukleinsaüre und ihre verwendung in der diagnose, hoch- durchsatz screeningsverfahren
DE60026199T2 (de) 2000-05-18 2006-11-23 Geneart Ag Synthetische Gene für gagpol und deren Verwendungen
US6919204B2 (en) * 2000-09-29 2005-07-19 Sangamo Biosciences, Inc. Modulation of gene expression using localization domains
DE10053781B4 (de) 2000-10-30 2008-07-03 Geneart Ag Kernexportreportersystem
EP1373535B1 (fr) 2001-04-05 2010-03-10 Millipore Corporation Expression genique amelioree
WO2002099105A2 (fr) 2001-06-05 2002-12-12 Cellectis Procede d'ecriture ou de reecriture d'une sequence polynucleotidique possedant un contenu predefini de dinucleotides cpg
US7576066B2 (en) * 2002-07-03 2009-08-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7569553B2 (en) * 2002-07-03 2009-08-04 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7605138B2 (en) * 2002-07-03 2009-10-20 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
AR040575A1 (es) * 2002-07-16 2005-04-13 Advisys Inc Plasmidos sinteticos optimizados en codones de expresion en mamiferos
DE10260805A1 (de) * 2002-12-23 2004-07-22 Geneart Gmbh Verfahren und Vorrichtung zum Optimieren einer Nucleotidsequenz zur Expression eines Proteins
US8224574B2 (en) 2004-05-12 2012-07-17 Northrop Grumman Guidance And Electronics Company, Inc. System for multiple navigation components
DE102004037611B4 (de) * 2004-08-03 2013-10-02 Geneart Ag Induzierbare Genexpression
BRPI0513081A (pt) 2004-08-03 2008-04-22 Geneart Ag método para modular a expressão gênica pela alteração do conteúdo de cpg, sistema de expressão, medicamento que o compreende e respectivos usos
DE102007052344B3 (de) * 2007-11-02 2009-03-12 Geneart Ag Selektion kodierender Nukleinsäure-Konstrukte auf Abwesenheit von Frameshift-Mutationen
EP2970965A2 (fr) * 2013-03-15 2016-01-20 Pronai Therapeutics, Inc. Adni pour la modulation de gènes

Also Published As

Publication number Publication date
DE502005008794D1 (de) 2010-02-11
EP1776460B2 (fr) 2013-12-25
US20210155940A1 (en) 2021-05-27
US20190270999A1 (en) 2019-09-05
CA2575490A1 (fr) 2006-02-16
AU2005270430A1 (en) 2006-02-16
WO2006015789A2 (fr) 2006-02-16
KR20070041605A (ko) 2007-04-18
AU2005270430B2 (en) 2008-06-12
BRPI0513081A (pt) 2008-04-22
EP1776460B8 (fr) 2014-02-26
JP2008507986A (ja) 2008-03-21
EP1776460A2 (fr) 2007-04-25
US20090324546A1 (en) 2009-12-31
DK1776460T3 (da) 2010-04-12
WO2006015789A3 (fr) 2006-06-01
MX2007001292A (es) 2007-07-04
HK1100089A1 (en) 2007-09-07
KR101222628B1 (ko) 2013-01-16
ATE453716T1 (de) 2010-01-15
IL180786A0 (en) 2007-06-03
US20150104832A1 (en) 2015-04-16
US10273486B2 (en) 2019-04-30
JP4550115B2 (ja) 2010-09-22
US8859275B2 (en) 2014-10-14
EP1776460B1 (fr) 2009-12-30

Similar Documents

Publication Publication Date Title
IL180786A (en) A gene expression modulation method by modifying cpg content
CN101035899B (zh) 通过改变CpG含量来调节基因表达的方法
KR102535670B1 (ko) 아데노바이러스 폴리뉴클레오티드 및 폴리펩티드
KR102287184B1 (ko) 개선된 단백질 또는 펩타이드 발현을 위한 인공 핵산 분자
EP1002091B1 (fr) Sequence d'acides nucleiques et procede pour exprimer, de maniere selective, une proteine dans une cellule ou un tissu cible
EP2333091B1 (fr) Vecteurs et méthodes pour immunisation génétique
JP4024830B2 (ja) Hhv−7由来の組換ウイルスベクター、その製造方法、それを用いた宿主細胞の形質転換方法、それにより形質転換された宿主細胞およびそれを用いた遺伝子治療方法
KR101841350B1 (ko) 이중 플라스미드 벡터를 포함하는 지방세포 표적 비바이러스성 유전자 전달 복합체
TW202237845A (zh) 用於涉及去胺作用之基因體編輯之多核苷酸、組合物及方法
JP2023145678A (ja) エプスタインバールウイルス抗原構築物
EP2138580B1 (fr) Vecteur pour une thérapie génique
EP1075529A1 (fr) Circuits moleculaires regulateurs permettant d'obtenir une activation soutenue de genes d'interet par un seul stress
CN113699186A (zh) 基因表达盒、慢病毒载体及其在治疗β地中海贫血症的应用
KR20230031929A (ko) 고릴라 아데노바이러스 핵산 서열 및 아미노산 서열, 이들을 함유하는 벡터, 및 이의 용도
CN111065408A (zh) 免疫原性组合物
CN116171326A (zh) 用于基因病症的核酸疗法
CN114045305B (zh) 多转座子系统
EP1233066B1 (fr) Vecteur peptide
CN110964741B (zh) 一种核定位信号fnb及其在提高碱基编辑效率中的应用
EP1856267B1 (fr) Vecteurs comprenant des nouveaux elements regulateurs
RU2779637C1 (ru) Содержащая рнк композиция для лечения опухолевых заболеваний
MENG Epstein-Barr Virus episome replication and transcription
KR20030079214A (ko) 야생형 아데노바이러스 혈청형 5의 제한된 초기유전자1을 포함하는 발현벡터 및 이를 포함하는 동물 세포주

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed